Prognostic significance of sirtuin 2 protein nuclear localization in glioma: An immunohistochemical study

Imaoka,Natsuko; Hiratsuka,Masaharu; Osaki,Mitsuhiko; Kamitani,Hideki; Kambe,Atsushi; Fukuoka,Junya; Kurimoto,Masanori; Nagai,Shoichi; Okada,Futoshi; Watanabe,Takashi; Ohama,Eisaku; Kato,Shinsuke; Oshimura,Mitsuo

doi:10.3892/or.2012.1872

September 2012 Volume 28 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

September 2012 Volume 28 Issue 3

Full Size Image

Article

Prognostic significance of sirtuin 2 protein nuclear localization in glioma: An immunohistochemical study

Authors:
- Natsuko Imaoka
- Masaharu Hiratsuka
- Mitsuhiko Osaki
- Hideki Kamitani
- Atsushi Kambe
- Junya Fukuoka
- Masanori Kurimoto
- Shoichi Nagai
- Futoshi Okada
- Takashi Watanabe
- Eisaku Ohama
- Shinsuke Kato
- Mitsuo Oshimura
View Affiliations / Copyright

Affiliations: Department of Biomedical Science, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Science, Tottori University, Yonago, Tottori 683-8503, Japan, Division of Molecular and Cell Genetics, School of Life Science, Tottori University Faculty of Medicine, Yonago, Tottori 683-8503, Japan, Division of Neurosurgery, Department of Brain and Neurosciences,Tottori University Faculty of Medicine, Yonago, Tottori 683-8503, Japan, Department of Surgical Pathology, Toyama University Hospital, University of Toyama, Sugitani, Toyama 930-0194, Japan, Department of Neurosurgery, Faculty of Medicine, University of Toyama, Sugitani, Toyama 930-0194, Japan, Division of Pathological Biochemistry, School of Life Science, Tottori University Faculty of Medicine, Yonago, Tottori 683-8503, Japan, Division of Neuropathology, Department of Brain and Neurosciences, Tottori University Faculty of Medicine, Yonago, Tottori 683-8503, Japan
Pages: 923-930
|
Published online on: June 19, 2012

https://doi.org/10.3892/or.2012.1872
Expand metrics +

Abstract

The sirtuin 2 (SIRT2) protein is a member of the sirtuin family and homologous to Sir2 (silent information regulator 2) of Saccharomyces cerevisiae. To assess the pathobiological significance of SIRT2 protein expression and/or subcellular localization in human glioma, we examined SIRT2 protein expression in human gliomas using a polyclonal anti-SIRT2 antibody and immunohistochemistry. In this study, samples from 23 patients with glioblastoma (GB, grade IV), 8 patients with diffuse astrocytoma (DA, grade II) and 5 healthy individuals were examined. We established a SIRT2 labeling index (SIRT2-LI) that represents the percentage of cells with SIRT2 localized to the nucleus. The mean SIRT2-LI was 65.8±18.6 in GB samples, 41.2±22.8 in DA samples, and 28.6±12.3 in normal control samples. The SIRT2-LI of GB samples was significantly higher than that of normal control samples (P<0.01, Mann-Whitney's U-test) and that of DA samples (P<0.05). Moreover, the SIRT2-LI was positively correlated with malignant progression. Specifically, samples from patients with GB were divided into two groups, low SIRT2-LI (<60%) and high SIRT2-LI (≥60%), and the patients with low SIRT2-LI samples survived significantly longer than patients with high SIRT2-LI samples (P<0.05, Kaplan-Meier method and log-rank test). In conclusion, SIRT2-LI was indicative of glioma malignancy, and it may be predictive of GB patient survival.

View Figures

View References

1	Huse JT and Holland EC: Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer. 10:319–331. 2010. View Article : Google Scholar : PubMed/NCBI
2	Frederick L, Wang XY, Eley G and James CD: Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 60:1383–1387. 2000.PubMed/NCBI
3	Shete S, Hosking FJ, Robertson LB, et al: Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 41:899–904. 2009. View Article : Google Scholar : PubMed/NCBI
4	Wrensch M, Jenkins RB, Chang JS, et al: Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet. 41:905–908. 2009. View Article : Google Scholar : PubMed/NCBI
5	Di Rocco F, Carroll RS, Zhang J and Black PM: Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. Neurosurgery. 42:341–346. 1998.PubMed/NCBI
6	Xiao A, Wu H, Pandolfi PP, Louis DN and Van Dyke T: Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell. 1:157–168. 2002. View Article : Google Scholar : PubMed/NCBI
7	Ohgaki H and Kleihues P: Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 170:1445–1453. 2007. View Article : Google Scholar : PubMed/NCBI
8	Hiratsuka M, Inoue T, Toda T, et al: Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun. 309:558–566. 2003. View Article : Google Scholar : PubMed/NCBI
9	Michan S and Sinclair D: Sirtuins in mammals: insights into their biological function. Biochem J. 404:1–13. 2007. View Article : Google Scholar : PubMed/NCBI
10	North BJ and Verdin E: Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis. PLoS One. 2:e7842007. View Article : Google Scholar : PubMed/NCBI
11	Blander G and Guarente L: The Sir2 family of protein deacetylases. Annu Rev Biochem. 73:417–435. 2004. View Article : Google Scholar : PubMed/NCBI
12	Pandithage R, Lilischkis R, Harting K, et al: The regulation of SIRT2 function by cyclin-dependent kinases affects cell motility. J Cell Biol. 180:915–929. 2008. View Article : Google Scholar : PubMed/NCBI
13	Harting K and Knoll B: SIRT2-mediated protein deacetylation: An emerging key regulator in brain physiology and pathology. Eur J Cell Biol. 89:262–269. 2010. View Article : Google Scholar : PubMed/NCBI
14	Inoue T, Nakayama Y, Yamada H, et al: SIRT2 downregulation confers resistance to microtubule inhibitors by prolonging chronic mitotic arrest. Cell Cycle. 8:1279–1291. 2009. View Article : Google Scholar : PubMed/NCBI
15	Inoue T, Hiratsuka M, Osaki M and Oshimura M: The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation. Cell Cycle. 6:1011–1018. 2007. View Article : Google Scholar : PubMed/NCBI
16	Inoue T, Hiratsuka M, Osaki M, et al: SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress. Oncogene. 26:945–957. 2007. View Article : Google Scholar : PubMed/NCBI
17	Kato M, Brijlall D, Adler SA, Kato S and Herz F: Effect of hyperosmolarity on alkaline phosphatase and stress-response protein 27 of MCF-7 breast cancer cells. Breast Cancer Res Treat. 23:241–249. 1992. View Article : Google Scholar : PubMed/NCBI
18	Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
19	Fukuoka J, Fujii T, Shih JH, et al: Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res. 10:4314–4324. 2004. View Article : Google Scholar : PubMed/NCBI
20	Werner HB, Kuhlmann K, Shen S, et al: Proteolipid protein is required for transport of sirtuin 2 into CNS myelin. J Neurosci. 27:7717–7730. 2007. View Article : Google Scholar : PubMed/NCBI
21	Holland EC: Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet. 2:120–129. 2001. View Article : Google Scholar : PubMed/NCBI
22	Zhu Y, Guignard F, Zhao D, et al: Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell. 8:119–130. 2005. View Article : Google Scholar : PubMed/NCBI
23	Nahhas F, Dryden SC, Abrams J and Tainsky MA: Mutations in SIRT2 deacetylase which regulate enzymatic activity but not its interaction with HDAC6 and tubulin. Mol Cell Biochem. 303:221–230. 2007. View Article : Google Scholar : PubMed/NCBI
24	Lee YS, Lim KH, Guo X, et al: The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res. 68:7561–7569. 2008. View Article : Google Scholar : PubMed/NCBI
25	Schiffer D, Cavalla P, Chio A, Richiardi P and Giordana MT: Proliferative activity and prognosis of low-grade astrocytomas. J Neurooncol. 34:31–35. 1997. View Article : Google Scholar : PubMed/NCBI
26	Di X, Nishizaki T, Harada K, Kajiwara K, Nakayama H and Ito H: Proliferative potentials of glioma cells and vascular components determined with monoclonal antibody MIB-1. J Exp Clin Cancer Res. 16:389–394. 1997.
27	Uematsu M, Ohsawa I, Aokage T, et al: Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index. J Neurooncol. 72:231–238. 2005. View Article : Google Scholar : PubMed/NCBI
28	Johannessen AL and Torp SH: The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res. 12:143–147. 2006. View Article : Google Scholar : PubMed/NCBI
29	Moskowitz SI, Jin T and Prayson RA: Role of MIB1 in predicting survival in patients with glioblastomas. J Neurooncol. 76:193–200. 2006. View Article : Google Scholar : PubMed/NCBI
30	Rushing EJ, Sandberg GD and Horkayne-Szakaly I: High-grade astrocytomas show increased Nestin and Wilms' tumor gene (WT1) protein expression. Int J Surg Pathol. 18:255–259. 2010. View Article : Google Scholar : PubMed/NCBI
31	Ducray F, Idbaih A, Wang XW, Cheneau C, Labussiere M and Sanson M: Predictive and prognostic factors for gliomas. Expert Rev Anticancer Ther. 11:781–789. 2011. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Prognostic significance of sirtuin 2 protein nuclear localization in glioma: An immunohistochemical study

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Related Articles